Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses
June 6th 2021A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.
Synovial Sarcoma Sees Impressive Responses With T-Cell Therapy Afamitresgene Autoleucel
June 5th 2021Results of the phase 2 SPEARHEAD-1 trial were presented at the 2021 ASCO Annual Meeting, with a high overall response rate reported with afamitresgene autoleucel in advanced synovial sarcoma or myxoid/round cell liposarcoma.
Expert Looks Forward to Potentially Practice-Changing Presentations at ASCO 2021
June 3rd 2021CancerNetwork® sat down with Alison Schram, MD, to discuss her thoughts on research with the greatest potential to positively influence patient care being presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Jun J. Mao, MD, MSCE, on Non-Pharmacological Pain Management in Cancer Survivors
July 10th 2020At the 2020 ASCO Virtual Program, Jun J. Mao, MD, MSCE, presented a study designed to evaluate the comparative effectiveness of electro-acupuncture and auricular acupuncture versus usual care in managing pain in cancer survivors.
Fumiko Chino, MD, on Medicare’s Impact on Cancer Mortality Rates
June 25th 2020In a recent interview with CancerNetwork, Fumiko Chino, MD, discussed the need to evaluate Medicare’s impact on cancer mortality rates, and moreover, what she and her colleagues found in a recent study presented at the 2020 ASCO Virtual Program.
Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer Care
June 15th 2020Roy S. Herbst, MD, PhD, presented a late breaking abstract on behalf of his colleagues regarding the ADAURA trial, which analyzed osimertinib as an adjuvant therapy to treat patients with non-small cell lung cancer.
Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial
June 3rd 2020Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.